Pulmonx Corporation (LUNG) 株式分析

企業概要

Pulmonx Corporation is a commercial-stage medical technology enterprise dedicated to delivering minimally invasive therapeutic solutions for patients suffering from severe emphysema, a specific manifestation of chronic obstructive pulmonary disease. The corporation operates within the healthcare sector and the medical devices industry, providing specialized tools that facilitate targeted pulmonary interventions without extensive surgical procedures. Currently, the company employs 296 individuals and maintains a market capitalization of $57.44M alongside annual revenue of $90.50M over the trailing twelve-month period. These valuation and revenue figures indicate that Pulmonx holds a niche position in the specialized medical device market, characterized by a relatively modest market cap that reflects its status as a small-cap biotechnology or medical technology entity rather than a large-cap blue-chip firm.

財務健全性

The company reported revenue of $90.50M for the trailing twelve months, yet it posted a net income loss of $54,003,000 and an EBITDA of $-52,609,000, revealing a significant gap between top-line generation and bottom-line profitability driven by high operational expenses. The free cash flow stands at $-12,531,250, which indicates that the company is currently consuming cash reserves to fund operations and potentially R&D initiatives rather than generating surplus liquidity for distribution or aggressive debt repayment. Profitability analysis shows a gross margin of 74.2%, suggesting efficient manufacturing or sales pricing on core products, contrasted sharply by an operating margin of -43.8% and a profit margin of -59.7% that highlight substantial overhead costs eriding operating income before interest and taxes. Regarding liquidity and leverage, the firm holds $69.75M in cash against $56.36M in debt, resulting in a debt-to-equity ratio of 104.15 that suggests a leveraged balance sheet where liabilities exceed equity. Despite the leverage, the current ratio of 5.07 demonstrates robust short-term liquidity, indicating the company possesses more than five times the current assets necessary to cover its current liabilities. Return metrics further illustrate the financial reality, with a return on equity of -77.2% and a return on assets of -23.0%, signaling that management is currently generating negative returns on the capital invested by shareholders and the asset base.

バリュエーション評価

Valuation metrics for Pulmonx present a complex picture given the negative earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -1.35, implying that future earnings estimates are expected to remain negative or that the market is pricing the stock based on non-earnings fundamentals. The price-to-book ratio is 1.05, indicating that the market values the company at approximately one times its book value, which suggests the stock is not trading at a significant premium or discount relative to the net asset value recorded on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 0.63 and an EV/EBITDA of -0.84, which suggest the market is valuing the firm primarily on its revenue generation capabilities and asset base rather than earnings power. In terms of trading range, the stock has seen a 52-week high of $6.77 and a 52-week low of $1.13, placing the current valuation context within a wide volatility band that underscores the speculative nature of the investment. The beta value is 0.19, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting a low-correlation asset that may not move in tandem with general equity market swings.

Growth & Income

Growth dynamics are characterized by a revenue decline of -4.9% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income, implying that the company is in a contractionary phase regarding top-line sales and lacks the earnings base to measure traditional growth rates. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders, meaning the capital is theoretically available for reinvestment into growth initiatives or to service debt obligations. The absence of a dividend yield confirms that Pulmonx is a non-dividend payer, a profile typical of companies in the development or early commercial stage that prioritize capital allocation toward operational expansion over shareholder returns. Overall, the growth and income profile reflects a company experiencing revenue contraction and negative earnings, offering no current income stream and requiring capital preservation strategies rather than growth-at-any-cost expansion.